For research and educational purposes only. Not medical advice.

Inclisiran Reference

Educational, not medical advice reference for Inclisiran: Metabolic; regulatory status, evidence posture, source review, and schedule notes. Als…

Plain English

What it is
Inclisiran, sold under the brand name Leqvio, is an FDA-approved prescription medicine given as a shot under the skin by a healthcare provider. It is a small interfering RNA, a type of drug that lowers a liver protein called PCSK9 so the liver can pull more LDL, the bad cholesterol, out of the blood.
What people use it for
It is approved to lower LDL cholesterol in adults who have high cholesterol. A feature people in the heart-health community highlight is that it needs only occasional injections over the year instead of a daily pill or more frequent shots, which can make staying on treatment easier.
What the science shows
In two large human trials (ORION-10 and ORION-11), it lowered LDL cholesterol by roughly half compared with a placebo. Its main side effect is a reaction at the injection spot, which the trials described as generally mild.
The catch
The large trial built to prove it actually prevents heart attacks and strokes (ORION-4) has not reported results yet, so that real-world heart benefit is not yet confirmed. It is a clinician-given prescription drug, not a supplement, and its label has been broadened over time to cover general high cholesterol, including first-line use.

Reference summary

ORION-10 (n=1,561, US patients with ASCVD) and ORION-11 (n=1,617, European patients with ASCVD or ASCVD-risk-equivalent) were pooled and published in Ray 2020 NEJM. Both trials reported approximately 50 percent reduction in LDL-C from baseline at day 510 versus placebo with twice-yearly maintenance dosing. The cardiovascular outcomes trial ORION-4 (n=15,000+) was designed but has not yet reported.

Regulatory and posture

Categories
Metabolic
Aliases
Leqvio, ALN-PCSsc, Small interfering RNA targeting PCSK9 mRNA
Evidence posture
human - LDL-C reduction is well-characterized; cardiovascular outcome trial (ORION-4) has not yet reported.
Regulatory status
FDA-approved as Leqvio (2021) as an adjunct to diet and maximally tolerated statin therapy for adults with HeFH or established atherosclerotic cardiovascular disease requiring additional LDL-C lowering.
Content review status
label verified

Selected public sources

Related tools